期刊文献+

周围动脉闭塞性疾病血管内皮活性物质水平的意义

Plasma concentration of endothelial vasoactive factors and their clin ical significance in patients with peripheral arterial occlusive disease
下载PDF
导出
摘要 目的 探讨老年周围动脉闭塞性疾病 (peripheralarterialocclusivedisease ,PAOD)患者血管内皮活性因子水平及其临床意义。  方法  检测 3 3例确诊老年PAOD患者血浆一氧化氮 (NO)、内皮素 (ET)、血栓素B2(TXB2 )、6 酮 前列腺素F1α(6 K PGF1α)、P选择素 (PS)及血管性假血友病因子 (vWF) 6种血管内皮活性物质的水平 ,并分别与 40例健康老人及 3 0例具有心血管危险因素的非PAOD患者相比较。  结果  老年PAOD组的NO[(2 8 88± 8 54) μmol·L- 1]和 6 K PGF1α[(83 47± 13 67)ng·L- 1]水平显著低于健康老年组及心血管危险因素组 ,而ET[(95 0 9± 49 18)ng·L- 1]和TXB2 [(664 4± 3 3 1 8)ng·L- 1]、PS[(14 0 6± 2 18) μg·L- 1]及vWF[(10 4 42± 3 1 4) % ]水平显著高于健康对照组和心血管危险因素组。 结论 老年PAOD患者内皮功能失调 ;积极的控制心血管病危险因素 。 Objective To detect the plasma concentration of endothelial vasoa ctive factors in the elderly patients with peripheral arterial occlusive disease (PAOD).MethodsPlasma nitric oxide (NO ), endothelin (ET), thromboxane B 2 (TXB 2),6-keto-PGF 1α (6-K-PGF 1α ), P-selectin (PS), von Wille brand factor (vWF) were measured in 33 PAOD patients, 40 old healthy controls and 30 non-PAOD patients with cardiac risk factors. The results were analyzed. Results The levels of NO and 6-K-PGF 1α were (28.88±8.54)μmol·L -1 and (83.47±13.67)ng·L -1 , and the concentrations of ET, TXB 2 , PS and vWF were (95.09±49.18)ng· L -1 , (664.4±331.8)ng·L -1 , (14.06±2.18)μg·L -1 and (104.42±31.4)% in PAOD patients respectively. Conclusions The endo thelial function was impaired in the old PAOD patients, and more attention shou l d be paid to the control of cardiovascular risk factors and amelioration of vasc ular endothelial function in the treatment of PAOD.
出处 《实用老年医学》 CAS 2004年第1期19-21,共3页 Practical Geriatrics
基金 国家卫生部保健科研基金资助项目(20015006)
关键词 动脉闭塞性疾病 动脉硬化 内皮缩血管肽类 一氧化氮 老年人 Arterial occlusive diseases Arteriosclerosis Endothelins Nitric oxide Aged
  • 相关文献

参考文献2

二级参考文献21

  • 1强文安,刘捷,吕芳玲,刘枝俏,刘景生.^3H—精氨酸转化测定一氧化氮合酶活性[J].中华医学杂志,1996,76(8):567-571. 被引量:18
  • 2Stoffers HE, Rinkens PE, Kester AD, et al. The prevalence of asymptomalic and unrecognized peripheral agerial occlusive disease[J]. Int J Epidemiol, 1996,25(2) :282.
  • 3Toyota T, Hirata Y, Ikeda Y, et al. Lipo-PF1,a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin F1-controlled mulficenter trials in patients with diabetic Neuro pathy and leg ulcers[J]. Prostaglandins, 1993,46(5) :453.
  • 4Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990' s[J]. Nature, 1993,362: 801-809
  • 5Anderson TJ. Assessment and treatment of endothelium dysfunction in human[J] .J Am Call Cardiol, 1999,34:631-638.
  • 6Gimbrone MA. Vascular endothelium: art integrator of pathophysiologic stimuli in atherosclerasis[J]. Am J Cardiol, 1995,75:67B-70B.
  • 7Misko TP, Schilling RJ,Salvemini D, et al. A fluorometric assay for the measurement of nitrite in the biological samples[J]. Anal Biochem, 1993,214:11-16.
  • 8Everett SA, Dennis MF, Tozer GM, et al. Nitric oxide in biological fluids: Analysis of nitrite and nitrate by high-performance ion chromatography [J] .J Chromatogra, 1995,706:437-442.
  • 9钟慈声,孙安阳.一氧化氮的生物医学[A].孙安阳,周武雄.一氧化氮的检测[M],上海:上海医科大学出版社,1997,357-371.
  • 10Vallance P, Patteon S,Bhagat K, et al. Direct measurement of intric oxide in human beings[J]. Lancet, 1995,346:153-154.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部